1887
Research Open Access
Like 0

Abstract

Background

The Belgian COVID-19 vaccination campaign aimed to reduce disease spread and severity.

Aim

We estimated SARS-CoV-2 variant-specific vaccine effectiveness against symptomatic infection (VEi) and hospitalisation (VEh), given time since vaccination and prior infection.

Methods

Nationwide healthcare records from July 2021 to May 2022 on testing and vaccination were combined with a clinical hospital survey. We used a test-negative design and proportional hazard regression to estimate VEi and VEh, controlling for prior infection, time since vaccination, age, sex, residence and calendar week of sampling.

Results

We included 1,932,546 symptomatic individuals, of whom 734,115 tested positive. VEi against Delta waned from an initial estimate of 80% (95% confidence interval (CI): 80–81) to 55% (95% CI: 54–55) 100–150 days after the primary vaccination course. Booster vaccination increased initial VEi to 85% (95% CI: 84–85). Against Omicron, an initial VEi of 33% (95% CI: 30–36) waned to 17% (95% CI: 15–18), while booster vaccination increased VEi to 50% (95% CI: 49–50), which waned to 20% (95% CI: 19–21) 100–150 days after vaccination. Initial VEh for booster vaccination decreased from 96% (95% CI: 95–96) against Delta to 87% (95% CI: 86–89) against Omicron. VEh against Omicron waned to 73% (95% CI: 71–75) 100–150 days after booster vaccination. While recent prior infections conferred higher protection, infections occurring before 2021 remained associated with significant risk reduction against symptomatic infection. Vaccination and prior infection outperformed vaccination or prior infection only.

Conclusion

We report waning and a significant decrease in VEi and VEh from Delta to Omicron-dominant periods. Booster vaccination and prior infection attenuated these effects.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.26.2200768
2023-06-29
2024-02-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.26.2200768
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/26/eurosurv-28-26-4.html?itemId=/content/10.2807/1560-7917.ES.2023.28.26.2200768&mimeType=html&fmt=ahah

References

  1. Catteau L, Haarhuis F, Dequeker S, Vandael E, Stouten V, Litzroth A, et al. Surveillance van de COVID-19 vaccinatie in Belgische woonzorgcentra. Resultaten tot 24 maart 2021. Wettelijk depotnummer: D/2021/14.440/32. Brussels: Sciensano; 2021. Flemish. Available from: https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_THEMATIC%20REPORT_SURVEILLANCE%20VAN%20DE%20VACCINATIE%20IN%20BELGISCHE%20WOONZORGCENTRA.pdf
  2. Catteau L, Billuart M, Serrien B, Hubin P, Haarhuis F, Lizroth A, et al. Surveillance van COVID-19 vaccinatie bij zorgverleners in België. Intermediaire resultaten tot en met 31 mei 2021. Wettelijk depotnummer: D/2021/14.440/46. Brussels: Sciensano; 2021. Flemish. Available from: https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_THEMATIC%20REPORT_SURVEILLANCE_VAN_DE_VACCINATIE_BIJ_ZORGVERLENERS_1.pdf
  3. Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, et al. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine. 2022;40(22):3027-37.  https://doi.org/10.1016/j.vaccine.2022.04.025  PMID: 35459558 
  4. Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022;375(6581):678-80.  https://doi.org/10.1126/science.abn7591  PMID: 35040667 
  5. Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B, et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill. 2022;27(4):2101196.  https://doi.org/10.2807/1560-7917.ES.2022.27.4.2101196  PMID: 35086609 
  6. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5(9):e2232760.  https://doi.org/10.1001/jamanetworkopen.2022.32760  PMID: 36136332 
  7. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532-46.  https://doi.org/10.1056/NEJMoa2119451  PMID: 35249272 
  8. Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, et al. Assessment of neutralizing antibody response against SARS-CoV-2 variants after 2 to 3 doses of the BNT162b2 mRNA COVID-19 vaccine. JAMA Netw Open. 2022;5(5):e2210780.  https://doi.org/10.1001/jamanetworkopen.2022.10780  PMID: 35532938 
  9. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022;27(9):2200121.  https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121  PMID: 35241215 
  10. Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022;13(1):3602.  https://doi.org/10.1038/s41467-022-30681-1  PMID: 35739094 
  11. Bellusci L, Grubbs G, Zahra FT, Forgacs D, Golding H, Ross TM, et al. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Nat Commun. 2022;13(1):4617.  https://doi.org/10.1038/s41467-022-32298-w  PMID: 35941152 
  12. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376(6593):eabn4947.  https://doi.org/10.1126/science.abn4947  PMID: 35289632 
  13. Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, et al. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022;12(1):1438.  https://doi.org/10.1038/s41598-022-05325-5  PMID: 35082344 
  14. Sciensano. Belgium COVID-19 epidemiological situation- variants, baseline surveillance. Brussels: Sciensano; 2022. Available from: https://datastudio.google.com/embed/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/urrUC
  15. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org
  16. Therneau T. A Package for Survival Analysis in R R package version 3.5-5. 2023. Available from: https://CRAN.R-project.org/package=survival
  17. Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E, et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med. 2022;28(3):496-503.  https://doi.org/10.1038/s41591-022-01715-4  PMID: 35090165 
  18. Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al. Coronavirus Disease 19 (COVID-19) vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during Delta-dominant and Omicron-dominant periods in Japan: A multicenter prospective case-control study (factors associated with SARS-CoV-2 infection and the effectiveness of COVID-19 vaccines study. Clin Infect Dis. 2023;76(3):e108-15.  https://doi.org/10.1093/cid/ciac635  PMID: 35918782 
  19. Higdon MM, Baidya A, Walter KK, Patel MK, Issa H, Espié E, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022;22(8):1114-6.  https://doi.org/10.1016/S1473-3099(22)00409-1  PMID: 35752196 
  20. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21-34.  https://doi.org/10.1056/NEJMoa2203965  PMID: 35704396 
  21. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494-6.  https://doi.org/10.1056/NEJMc2119270  PMID: 34965358 
  22. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. , Influenza and Other Viruses in the Acutely Ill (IVY) Network. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.  https://doi.org/10.1136/bmj-2021-069761  PMID: 35264324 
  23. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021;602(7898):654-6.  https://doi.org/10.1038/s41586-021-04387-1  PMID: 35016196 
  24. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639-51.  https://doi.org/10.1001/jama.2022.0470  PMID: 35060999 
  25. Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijočević H, et al. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13(1):153.  https://doi.org/10.1038/s41467-021-27649-y  PMID: 35013191 
  26. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. , COVID-19 Genomics UK (COG-UK) consortium. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12.  https://doi.org/10.1016/S0140-6736(22)00462-7  PMID: 35305296 
  27. Van Goethem N, Chung PYJ, Meurisse M, Vandromme M, De Mot L, Brondeel R, et al. Clinical severity of SARS-CoV-2 Omicron variant compared with Delta among hospitalized COVID-19 patients in Belgium during autumn and winter season 2021-2022. Viruses. 2022;14(6):1297.  https://doi.org/10.3390/v14061297  PMID: 35746768 
  28. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924-44.  https://doi.org/10.1016/S0140-6736(22)00152-0  PMID: 35202601 
  29. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-45.  https://doi.org/10.15585/mmwr.mm7104e3  PMID: 35085224 
  30. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun. 2022;13(1):5736.  https://doi.org/10.1038/s41467-022-33378-7  PMID: 36180428 
  31. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. , VEBIS-Lot4 working group. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. Euro Surveill. 2022;27(30):2200551.  https://doi.org/10.2807/1560-7917.ES.2022.27.30.2200551  PMID: 35904059 
  32. Gram MA, Emborg HD, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. PLoS Med. 2022;19(9):e1003992.  https://doi.org/10.1371/journal.pmed.1003992  PMID: 36048766 
  33. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379:e072141.  https://doi.org/10.1136/bmj-2022-072141  PMID: 36191948 
  34. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63.  https://doi.org/10.15585/mmwr.mm7107e2  PMID: 35176007 
  35. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022;10(7):689-99.  https://doi.org/10.1016/S2213-2600(22)00101-1  PMID: 35468336 
  36. Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022;185(11):1875-1887.e8.  https://doi.org/10.1016/j.cell.2022.04.009  PMID: 35523182 
  37. Alejo JL, Mitchell J, Chang A, Chiang TPY, Massie AB, Segev DL, et al. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA. 2022;327(11):1085-7.  https://doi.org/10.1001/jama.2022.1393  PMID: 35113143 
  38. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022;7(3):423-33.  https://doi.org/10.1038/s41564-021-01051-2  PMID: 35132197 
  39. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22(6):781-90.  https://doi.org/10.1016/S1473-3099(22)00143-8  PMID: 35366962 
  40. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. , SIREN Study Group. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-20.  https://doi.org/10.1056/NEJMoa2118691  PMID: 35172051 
  41. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556-67.  https://doi.org/10.1016/S1473-3099(22)00801-5  PMID: 36681084 
  42. Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. Sci Transl Med. 2022;14(645):eabn8543.  https://doi.org/10.1126/scitranslmed.abn8543  PMID: 35380448 
  43. Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, et al. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. Lancet Infect Dis. 2023;23(1):45-55.  https://doi.org/10.1016/S1473-3099(22)00578-3  PMID: 36152671 
  44. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. , UPenn COVID Processing Unit‡. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829.  https://doi.org/10.1126/science.abm0829  PMID: 34648302 
  45. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377-80.  https://doi.org/10.1056/NEJMc2202542  PMID: 35297591 
  46. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. , DMID 21-0012 Study Group. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046-57.  https://doi.org/10.1056/NEJMoa2116414  PMID: 35081293 
  47. Robilotti EV, Whiting K, Lucca A, Poon C, Jani K, McMillen T, et al. Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022. Clin Microbiol Infect. 2022;28(12):1624-8.  https://doi.org/10.1016/j.cmi.2022.07.017  PMID: 35931373 
  48. Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, et al. Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine. 2022;40(22):3027-37.  https://doi.org/10.1016/j.vaccine.2022.04.025  PMID: 35459558 
  49. Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68):eabn8014.  https://doi.org/10.1126/sciimmunol.abn8014  PMID: 35076258 
  50. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med. 2022;386(7):698-700.  https://doi.org/10.1056/NEJMc2119236  PMID: 35021005 
  51. Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, et al. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med (N Y). 2022;3(6):406-421.e4.  https://doi.org/10.1016/j.medj.2022.04.013  PMID: 35815933 
  52. Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infect Dis. 2022;22(7):931-3.  https://doi.org/10.1016/S1473-3099(22)00309-7  PMID: 35623379 
/content/10.2807/1560-7917.ES.2023.28.26.2200768
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error